NCT06023095

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY3502970	Administered orally.
DRUG	Placebo	Administered orally.

Timeline

• Start date: 2023-09-21
• Primary completion: 2024-07-29
• Completion: 2024-07-29
• First posted: 2023-09-05
• Last updated: 2024-08-27

Locations

3 sites across 1 country: China

Regulatory

• FDA-regulated drug study